Trial Profile
Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer (MBC) treated with pertuzumab (P) in the first-line in a real-world setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 22 Jan 2016 New trial record